- Home
- PANW vs NVO Comparison
PANW vs NVO Comparison
Compare PANW & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | NVO |
|---|---|---|
| Founded | 2005 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3B | 197.4B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | PANW | NVO |
|---|---|---|
| Price | $279.62 | $43.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 39 | 11 |
| Target Price | ★ $216.28 | $51.00 |
| AVG Volume (30 Days) | 8.6M | ★ 11.3M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $2,273,100,000.00 | N/A |
| Revenue This Year | $24.93 | N/A |
| Revenue Next Year | $19.97 | $3.70 |
| P/E Ratio | $353.61 | ★ $13.60 |
| Revenue Growth | ★ 29.04 | N/A |
| 52 Week Low | $139.57 | $35.12 |
| 52 Week High | $302.95 | $71.80 |
Technical Indicators
Market Signals| Indicator | PANW | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 52.92 |
| Support Level | $179.81 | $43.35 |
| Resistance Level | $302.95 | $46.05 |
| Average True Range (ATR) | 13.67 | 1.37 |
| MACD | -2.91 | -0.18 |
| Stochastic Oscillator | 58.79 | 61.34 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.